The global intrauterine contraceptive devices market size was valued at USD 5.58 billion in 2025 and is projected to grow from USD 5.79 billion in 2026 to USD 7.82 billion by 2034, registering a CAGR of 3.82% during the forecast period from 2026 to 2034. Europe dominated the intrauterine contraceptive devices market with a market share of 34.2% in 2025.
The Intrauterine Contraceptive Devices (IUCD) Market refers to the global industry involved in the development, manufacturing, distribution, and sale of intrauterine devices used for long-term, reversible contraception. These devices, including hormonal and copper-based IUCDs, are inserted into the uterus to prevent pregnancy. Market growth is driven by increasing awareness of family planning, rising demand for effective contraceptive solutions, and advancements in reproductive healthcare technologies.
Download a Free Sample To learn more about this report,
Shift Toward Longer-Acting Contraceptive Options
The intrauterine contraceptive devices market analysis demands for reliable contraception with minimal user involvement is shifting preferences toward long-acting reversible methods, supporting greater adoption of IUDs; WHO states that copper IUDs can provide protection for 10–12 years, while hormonal IUDs can last 3–8 years, depending on the product. The low-maintenance nature of these devices is further supporting their appeal, as both copper and hormonal IUDs provide highly effective contraception without requiring daily user action.
Greater Emphasis on Person-Centered Contraceptive Choice
Individual reproductive goals, health conditions, and personal preferences are increasingly shaping contraceptive decisions, strengthening demand for person-centered IUD selection; WHO’s 2025 Medical Eligibility Criteria includes more than 2,000 recommendations across 25 contraceptive methods based on medical and physiological characteristics. For instance, the updated WHO guidance emphasizes informed choice and access to the contraceptive method that best suits individual needs, supporting more tailored use of intrauterine contraceptive devices.
Growth in Public-Sector Contraceptive Procurement and Expansion of Family Planning Services in Underserved Regions Drive Market
Government purchasing of IUDs creates stable institutional demand and gives manufacturers greater visibility over recurring order volumes.Public procurement programs also improve product availability through distribution across hospitals, primary health centers, and other public facilities.India’s public health system, for example, supplies IUCD 380A and Cu IUCD 375 through multiple levels of facilities, supporting consistent market demand.Such procurement activity strengthens the supply chain and supports broader adoption of IUD products.
Family planning service coverage in underserved areas brings IUD products to populations with limited access to contraceptive care. Healthcare facilities, trained providers, and outreach programs increase the number of locations where IUD insertion services are available. India’s Mission Parivar Vikas expanded family planning services across high-fertility districts, while public facilities provide IUD services through trained healthcare workers. Wider service coverage increases the potential user base and supports sustained demand for IUDs.
Misinformation and Social Stigma and Infrastructure and Follow-Up Requirements Limit Market Expansion
Misinformation and social stigma around IUD safety, fertility, and eligibility can discourage potential users from considering the method. Limited access to accurate counseling allows myths and social opposition to influence contraceptive decisions, reducing demand and acceptance. Provider-led education and reliable contraceptive information remain important for addressing these concerns and improving confidence in IUD use. Lower acceptance limits the conversion of unmet contraceptive needs into IUD adoption and slows market growth.
IUD service infrastructure and follow-up capacity influence the availability and continuity of services, particularly in underserved areas. Limited trained personnel, facility capacity, and follow-up services can restrict safe insertion and management of complications, reducing continued adoption. Gaps in referral networks and post-insertion care can further discourage healthcare providers from expanding IUD services in remote locations. Service limitations reduce effective market access and constrain demand growth across regions with weaker healthcare systems.
Integration of Digital Contraceptive Counseling and Development of Next-Generation IUD Designs Generate Expansion Opportunities
Digital health platforms and telehealth providers are key beneficiaries, with opportunities to connect users with licensed contraceptive providers and pre-insertion counseling. Twentyeight Health, for example, offers online contraception consultations and has partnered with Clue to connect users with provider-led birth control counseling. Such platforms can generate revenue through consultation services, memberships, partnerships, and broader contraceptive-care offerings. Healthcare providers and IUD manufacturers can also use these channels to improve product education and reach potential users earlier in the decision-making process.
Medical device manufacturers and reproductive-health companies can benefit from demand for IUDs with improved insertion, comfort, usability, and clinical performance. New device designs can create differentiated product portfolios and support premium pricing while expanding adoption among users concerned about existing IUD experiences. The opportunity provides manufacturers with additional revenue through new product launches, upgraded device platforms, and stronger healthcare-provider demand.
Supply Chain & Raw Material Volatility and Dependence on Procurement & Distribution Networks Reduces Growth Potential
Material availability and supply chain reliability create operational challenges for IUD manufacturers that depend on specialized components and medical-grade materials. Production delays or higher input costs can disrupt inventory planning, increase manufacturing expenses, and reduce supply consistency across markets. For example, copper price volatility in 2026 has raised concerns about higher manufacturing costs for copper-dependent products, creating margin pressure for device manufacturers.
Procurement concentration and distribution network dependence can make revenue growth difficult for manufacturers that rely heavily on government tenders, donors, or centralized purchasing systems. Changes in funding, purchasing volumes, or distribution priorities can create uneven demand and leave suppliers with excess inventory or delayed orders. The 2025 reduction in U.S. foreign-aid funding left contraceptive supplies, including IUDs, stranded in warehouses and disrupted established distribution channels.
The Hormonal Intrauterine Devices market segment accounted for a share of 61.5% in 2025 due to their high contraceptive effectiveness, long-lasting protection, reduced menstrual bleeding and cramping, and growing preference for convenient, reversible birth-control methods.
Copper Intrauterine Devices also remain an important non-hormonal option, particularly among women seeking long-term contraception without the use of hormones. The availability of both hormonal and copper IUDs allows healthcare providers to offer options based on individual reproductive needs, preferences, and tolerance for hormonal contraception, supporting continued adoption across the market.
Request Customizationto receive a tailored report.
The Skyla market segment is expected to grow at a CAGR of 4.95% in forecast period 2026-2034, driven by increasing demand for low-dose hormonal contraception, its smaller size and suitability for women seeking a shorter-duration intrauterine option, and growing preference for convenient, reversible birth control methods. Other products, including Mirena, Paragard, Essure, Levosert, and emerging alternatives, continue to address diverse contraceptive preferences through hormonal and non-hormonal options, supporting overall product adoption across the market.
The hospitals market segment accounted for a share of 48.7% in 2025 due to the availability of specialized gynecological services, trained healthcare professionals, advanced facilities for IUD insertion, and growing patient preference for receiving contraceptive procedures in supervised clinical settings. Gynecology clinics and community healthcare centers also contribute to market expansion by improving access to contraceptive counseling, IUD insertion, follow-up care, and affordable family-planning services.
Speak to an Analystto discuss market opportunities.
The Europe intrauterine contraceptive devices market accounted for the largest regional share of 34.2% in 2025, driven by high awareness of long-acting reversible contraception, well-established healthcare systems, and favorable access to modern contraceptive methods across major European countries.
Germany is witnessing continued demand for long-acting reversible contraception, with Germany companies such as Bayer AG, Gedeon Richter, and CooperSurgical strengthening their presence through hormonal and copper IUD offerings. Germany’s population projections indicate continued demographic change through 2030 and beyond, with Destatis providing population forecasts by sex and single year of age through 2070, supporting continued demand planning for reproductive-health and contraceptive services.
In the U.K., demand for intrauterine contraceptive devices is benefiting from broad access to family-planning services and established reproductive healthcare infrastructure. The U.K. population is projected to reach 71.0 million by mid-2034, while the Office for National Statistics expects total fertility to remain relatively low at 1.38 children per woman in 2029, potentially sustaining demand for reliable and reversible contraceptive methods such as intrauterine devices.
France is gaining momentum in the intrauterine contraceptive devices market, supported by an established public healthcare system and widespread availability of contraceptive services. France’s latest population projections assume a total fertility rate of 1.45 children per woman from 2028 under the low scenario, while the average age at childbirth is projected to rise to 33.0 years by 2050, trends that could support continued use of long-acting and reversible contraceptive methods.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific intrauterine contraceptive devices market is expected to grow at a CAGR of 5.76% during the forecast period 2026–2034, showcasing the fastest-growing regional market, driven by rising awareness of long-acting contraception and improving access to reproductive healthcare.
Japan is experiencing continued demographic change, with the National Institute of Population and Social Security Research projecting the population to decline from 126.15 million in 2020 to 120.12 million by 2030, while the proportion of people aged 65 and over is projected to reach 30.8%, creating continued demand for accessible and effective reproductive-health and contraceptive services.
China’s population is undergoing significant demographic change, with the government reporting 323.38 million people aged 60 and over in 2025, representing 23.0% of the population, while national health policies continue to emphasize wider access to contraception and reproductive-health services, supporting demand for modern contraceptive options such as IUDs.
India’s relatively young population and continued family-planning needs are supporting demand for intrauterine contraceptive devices, with the Ministry of Health and Family Welfare reporting that 56.5% of women use modern contraceptive methods and 29 states have more than 70% of eligible couples in need of contraception, highlighting substantial scope for modern contraceptive adoption.
The North America intrauterine contraceptive devices market expansion is led by increasing adoption of long-acting reversible contraception and improving access to reproductive healthcare, with the market expected to grow at a CAGR of 4.18% during 2026–2034.
The U.S. Census Bureau projects that adults aged 65 and over will outnumber children by 2034, while CDC data show 10.5% of females aged 15–49 used long-acting reversible contraception in 2022–2023, indicating continued demand for effective, reversible contraceptive options such as IUDs. Expanding access to family-planning services and contraceptive counseling can further support adoption of intrauterine devices.
Canada projects the Canadian population to reach 57.4 million by 2075 under its medium-growth scenario, while the total fertility rate is projected at 1.24 children per woman by 2029/30, supporting continued demand for effective family-planning and reversible contraceptive methods. Growing emphasis on accessible reproductive healthcare is expected to create additional opportunities for long-acting contraceptive solutions such as IUDs.
The Middle East & Africa intrauterine contraceptive devices market demand is led by rising market demand for long-acting reversible contraception, increasing awareness of family-planning options, and improving access to reproductive healthcare, with the market accounting for 6% of the regional share in 2025.
The UAE’s population is projected to continue expanding through the coming decades, while continued demand for family-planning services and reproductive healthcare is expected to support opportunities for long-acting contraceptive methods such as IUDs.
Africa’s unmet need for modern contraception is expected to remain substantial through 2030, with UNFPA estimating that the number of women globally wanting to avoid or delay pregnancy but not using modern contraception could reach 271 million by 2030, highlighting significant opportunities to expand access to long-acting methods such as IUDs.
The intrauterine contraceptive devices market competitive landscape is moderately fragmented, with competition comprising global pharmaceutical and medical device companies, specialized contraceptive manufacturers, regional IUD producers, and emerging women’s health companies. Key players such as Bayer Healthcare, Agile Therapeutics, Fuji Latex Co., Ltd., Pfizer, and Reckitt Benckiser Group PLC collectively are estimated to account for approximately 40% of the global intrauterine contraceptive devices market share.
Established players compete primarily on brand recognition, clinical efficacy, regulatory approvals, product portfolio breadth, manufacturing capabilities, healthcare-provider relationships, and global distribution networks. Emerging and regional players in the intrauterine contraceptive devices market ecosystem compete through cost-effective products, differentiated device designs, improved insertion systems, hormone-free alternatives, localized distribution, and partnerships with healthcare providers and public-health organizations.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Asia Pacific Electrocardiograph (ECG) Market Size, Share Trend Analysis by 2034
Middle East and Africa Dental Intraoral Scanners Market Size, 2034
Artificial Lung Market Size, Share, Growth, Analysis, 2034
Bronchoscopes Market Size, Share, Growth, Analysis, Report, 2034
Aesthetic Threads Market Size, Share, Growth, Forecast, 2034
Middle East And Africa Diabetes Devices Market Size and Forecast 2034
We are featured on:
sales@straitsresearch.com